Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B London

Showing results (221-230 of 310) with videos related to

Pageof 31
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 30, 2016
Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group ProjectMark A Applebaum, Zalman Vaksman, Sang Mee Lee, et al.
Oncotarget|June 9, 2015
Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanismStefano J Mandriota, Linda J Valentijn, Laurence Lesne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2012
Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641Douglas R Strother, Wendy B London, Mary Lou Schmidt, et al.
British Journal of Haematology|May 29, 2020
The pyruvate kinase (PK) to hexokinase enzyme activity ratio and erythrocyte PK protein level in the diagnosis and phenotype of PK deficiencyHanny Al-Samkari, Kathryn Addonizio, Bertil Glader, et al.
Cancer Research|October 12, 2010
Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapyDavid C Delgado, Jacquelyn A Hank, Jill Kolesar, et al.
Cancer Letters|June 25, 2005
Epidural compression in neuroblastoma: Diagnostic and therapeutic aspectsBruno De Bernardi, Walentyna Balwierz, Joanna Bejent, et al.
International Journal of Molecular Imaging|October 11, 2012
Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology GroupSteven G Dubois, Ethan Geier, Vandana Batra, et al.
Pediatric Blood & Cancer|June 1, 2024
Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children's Oncology Group study ANBL0531Erin K Barr, Arlene Naranjo, Clare J Twist, et al.
Pediatric Blood & Cancer|November 6, 2024
Outcomes of patients with intermediate-risk neuroblastoma presenting with motor deficits relating to intraspinal tumor extension: A report from the Children's Oncology Group study ANBL0531Julie Voeller, Howard M Katzenstein, Arlene Naranjo, et al.
The Lancet. Child & Adolescent Health|September 28, 2025
Late effects after high-risk neuroblastoma (LEAHRN): a multicentre, cross-sectional cohort study from the Children's Oncology GroupTara O Henderson, Jenna K Bardwell, Pei-Chi Kao, et al.
Pageof 31

Showing results (221-230 of 310) with videos related to

Sort By:
Pageof 31
European Journal of Cancer (Oxford, England : 1990)|December 30, 2016
Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group ProjectMark A Applebaum, Zalman Vaksman, Sang Mee Lee, et al.
Oncotarget|June 9, 2015
Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanismStefano J Mandriota, Linda J Valentijn, Laurence Lesne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2012
Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641Douglas R Strother, Wendy B London, Mary Lou Schmidt, et al.
British Journal of Haematology|May 29, 2020
The pyruvate kinase (PK) to hexokinase enzyme activity ratio and erythrocyte PK protein level in the diagnosis and phenotype of PK deficiencyHanny Al-Samkari, Kathryn Addonizio, Bertil Glader, et al.
Cancer Research|October 12, 2010
Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapyDavid C Delgado, Jacquelyn A Hank, Jill Kolesar, et al.
Cancer Letters|June 25, 2005
Epidural compression in neuroblastoma: Diagnostic and therapeutic aspectsBruno De Bernardi, Walentyna Balwierz, Joanna Bejent, et al.
International Journal of Molecular Imaging|October 11, 2012
Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology GroupSteven G Dubois, Ethan Geier, Vandana Batra, et al.
Pediatric Blood & Cancer|June 1, 2024
Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children's Oncology Group study ANBL0531Erin K Barr, Arlene Naranjo, Clare J Twist, et al.
Pediatric Blood & Cancer|November 6, 2024
Outcomes of patients with intermediate-risk neuroblastoma presenting with motor deficits relating to intraspinal tumor extension: A report from the Children's Oncology Group study ANBL0531Julie Voeller, Howard M Katzenstein, Arlene Naranjo, et al.
The Lancet. Child & Adolescent Health|September 28, 2025
Late effects after high-risk neuroblastoma (LEAHRN): a multicentre, cross-sectional cohort study from the Children's Oncology GroupTara O Henderson, Jenna K Bardwell, Pei-Chi Kao, et al.
Pageof 31